

Algorae Pharmaceuticals – Notice of AGM Proceedings

Algorae Pharmaceuticals Limited (ASX:1AI) (**Company**) advises that, in accordance with ASX Listing Rule 3.13.1 and clause 7 of the Company's constitution, the next annual general meeting of the Company (**AGM**) is scheduled to be held at 12 Noon am (AEST) on Thursday, 02 November 2023.

In addition, the closing date for the receipt of nominations from persons wishing to be considered for election as a director is 21 September 2023. Any nominations must be received in writing no later than 5.00pm (AEST) on 21 September 2023 at the Company's registered office.

Shareholders will be advised of further details regarding the AGM in a separate notice of meeting, which will be provided to shareholders towards the end of September 2023 and will also be available on ASX's Company Announcements Platform and the Company's website at www.algoraepharma.com.

This announcement has been approved by the Board of Directors of Algorae Pharmaceuticals Limited.

End

For more information, please visit www.algoraepharma.com

Corporate and Media Enquiries

Mr Brad Dilkes - Director

P: +61 422 180 317

E: brad@lctglobal.com

Forward-looking Statements

This document may contain certain forward-looking statements, relating to Algorae's business, which can be identified by the use of forward-looking terminology such as "promising," "probable," "plans," "anticipated," "will," "project," "believe," "forecast," "expected," "estimated," "targeting," "aiming," "set to," "potential," "seeking to," "goal," "could provide," "intends," "is being developed," "could be," "on track," or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA's and other health authorities' requirements regarding any one or more product candidates, nor can there be any assurance that such product candidates will be approved by any health authorities for sale in any market or that they will reach any particular level of sales. In particular, management's expectations regarding the approval and commercialisation of the product candidates could be affected by, among other things, unexpected clinical trial results, including additional analysis of existing clinical data, and new clinical data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialise, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated, or expected. Algorae is providing this information and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.